CONTEXT: Observational studies are not the same as clinical trial and yet, until recently, we had to use the same tools…and that really didn’t go well | A new Continue Reading
AUTHOR: Russell Joyce | Director & Principal Consultant | Heath Barrowcliff Consulting CONTEXT: Operational Guidance for document management for your real-world research ‘trial master file’…we prefer to call it a Continue Reading
CONTEXT: Corporate press release | It does exactly what it says on the tin. READ TIME: 2 mins Quality Level Mean [1 – 10]: 3 1. “Feb. 24, 2021 11:00 Continue Reading
CONTEXT: An opinion piece on the value of data sets in biomedical and neuroimaging studies, but only where they are compatible | When we still don’t have a common charger for Continue Reading
CONTEXT: A claim that will no doubt be tested – “Regulatory-grade evidence”. What exactly constitutes regulatory-grade RWE? Time will tell as we move into a new era for RWR | Continue Reading
CONTEXT: A study title that may slip through unnoticed as it does not explicitly mention RWR, but an interesting study showing how RWE can inform physicians on the impact of Continue Reading
Speculative article on decentralised trials in the COVID era. Will they be here to stay or will the industry revert to pulling patients in for regular visits once we are Continue Reading
FULL TITLE: Meeting the Urgent Needs of People Living with Dementia Requires Addressing Existing Disparities in Care, and Ensuring Future Research Prioritizes Inclusivity and Real-World Studies – National Academies of Continue Reading
CONTEXT: A proper peer reviewed study article on a retrospective study based on an oncology registry in Canada highlighting the differences in outcomes for rural versus urban patients. READ TIME: Continue Reading
CONTEXT: A story of being in the right place at the right time for a SaaS provider| FDA’s increasing interest and support for high-quality RWE in the field of cannabinoid Continue Reading
